Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis

Company Overview

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Key Stats

• Today's Range: $2.33 to $3.78
• 50-Day Range: $2.29 to $6.69
• 52-Week Range: $2.21 to $19.71
• Volume: 12.62 million shs
• Average Volume: 1.14 million shs
• Market Capitalization: $219.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.60
• Consensus Rating: Buy

Phathom Pharmaceuticals Stock Analysis - MarketRank™

Phathom Pharmaceuticals scored higher than 83% of companies evaluated by MarketBeat, and ranked 173rd out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Phathom Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Phathom Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($4.78) to ($4.02) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Phathom Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Phathom Pharmaceuticals is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

21.93% of the float of Phathom Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Phathom Pharmaceuticals has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in Phathom Pharmaceuticals has recently decreased by 11.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Phathom Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Phathom Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

21.93% of the float of Phathom Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Phathom Pharmaceuticals has a short interest ratio ("days to cover") of 9.5.

Change versus previous month

Short interest in Phathom Pharmaceuticals has recently decreased by 11.85%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.50

News Sentiment

Phathom Pharmaceuticals has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Phathom Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

4 people have searched for PHAT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

2 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Phathom Pharmaceuticals insiders have sold 28.73% more of their company's stock than they have bought. Specifically, they have bought $13,000.00 in company stock and sold $16,735.00 in company stock.

Percentage Held by Insiders

23.00% of the stock of Phathom Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PHAT Stock Analysis - Frequently Asked Questions

How have PHAT shares performed this year?

Phathom Pharmaceuticals' stock was trading at $8.12 at the beginning of 2025. Since then, PHAT stock has decreased by 61.3% and is now trading at $3.14.
View the best growth stocks for 2025 here.

How were Phathom Pharmaceuticals' earnings last quarter?

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) released its earnings results on Thursday, November, 7th. The company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.57) by $0.25. The business earned $16.35 million during the quarter, compared to the consensus estimate of $12.54 million.
Read the conference call transcript.

When did Phathom Pharmaceuticals IPO?

Phathom Pharmaceuticals (PHAT) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 7,900,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI served as the underwriters for the IPO and Needham & Company was co-manager.

Who are Phathom Pharmaceuticals' major shareholders?

Phathom Pharmaceuticals' top institutional investors include Jennison Associates LLC (10.11%), Charles Schwab Investment Management Inc. (0.50%), Bank of New York Mellon Corp (0.16%) and XTX Topco Ltd (0.13%). Insiders that own company stock include Pharmaceutical Co Ltd Takeda, Terrie Curran, Azmi Nabulsi, Asit Parikh and Frank Karbe.
View institutional ownership trends.

How do I buy shares of Phathom Pharmaceuticals?

Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Phathom Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Phathom Pharmaceuticals investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), Waste Connections (WCN), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 5/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PHAT
• CIK: 1783183
• Web: www.phathompharma.com
• Phone: 877-742-8466
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $17.60
• High Stock Price Target: $28.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +460.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($5.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-201,590,000.00
• Net Margins: -1,292.14%
• Pretax Margin: -1,292.14%
• Return on Equity: N/A
• Return on Assets: -79.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.73
• Quick Ratio: 5.68

Sales & Book Value

• Annual Sales: $81.86 million
• Price / Sales: 2.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.27) per share
• Price / Book: -2.47

Miscellaneous

• Outstanding Shares: 69,814,000
• Free Float: 51,898,000
• Market Cap: $219.22 million
• Optionable: Optionable
• Beta: 0.15